Trial 4K-13-1


A Randomized Phase II Study of AMG386 With or Without Continued Anti-Vascular Endothelial Growth Factor (VEGF) Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib.

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Anti-Angiogenesis, Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  David Quinn, M.D.
Other Trial Staff:  Aaron Mejia, D.M., Lagrimas Ilagan, D.M., Taison Tran, Coordinator, Ernesto Duverger, D.M., Elysse Faye Ballon, Coordinator, Torsten Fischer, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.